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Abstract
Background: Neoadjuvant CRT may lead to significant tumor regression in patients with rectal cancer. Different
CRT regimens with consolidation chemotherapy may lead to increased rates of complete tumor regression. The
purpose of this study was to understand tumor metabolic activity following two different neoadjuvant CRT
regimens using sequential PET/CT imaging in two different intervals following RT.
Methods: Patients with cT2-4 N0-2 M0 rectal cancer treated by standard CRT (54Gy and 2 cycles of 5FU-based
chemotherapy) or extended CRT (54Gy and 6 cycles of 5FU-based chemotherapy) underwent sequential PET/CT
imaging at baseline, 6 weeks and 12 weeks from radiation completion.
Results: 99 patients undergoing standard CRT were compared to 12 patients undergoing CRT with consolidation
chemotherapy. Patients treated with consolidation CRT had increased rates of complete clinical or pathological
response (66 % vs. 23 %; p < 0.001). SUVmax variation between baseline and 6 weeks (88 % vs. 63 %; p < 0.001) and
between baseline and 12 weeks (90 % vs. 57 %; p < 0.001) were significantly more pronounced among patients
undergoing extended CRT with consolidation chemotherapy. An increase in SUVmax between 6 and 12 weeks was
observed in 51 % of patients undergoing standard and 18 % of patients undergoing consolidation CRT (p = 0.04).
Conclusions: Most of the reduction in tumor metabolism after neoadjuvant CRT occurs within the first 6 weeks
from RT completion. In patients undergoing CRT with consolidation chemotherapy, tumors are less likely to regain
metabolic activity between 6 and 12 weeks. Therefore, assessment of tumor response may be safely postponed to
12 weeks in patients undergoing extended CRT with consolidation chemotherapy.
Trial registration: NCT00254683
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Neoadjuvant chemoradiation therapy (CRT) is now con-
sidered one of the preferred treatment strategies for dis-
tal rectal cancer [1]. In addition to the potential benefits
in improved local disease control, neoadjuvant CRT may
result in significant tumor downsizing and tumor down-
staging [2]. Ultimately, complete tumor regression may
develop with no residual cancer cells found at pathology
following radical surgery [3, 4]. These patients with
complete pathological response (pCR) are associated
with improved oncological outcomes. Accurate identifi-
cation of these patients could potentially spare them
from major radical proctectomy and its considerable
postoperative morbidity, mortality and disturbances in
urinary, fecal and sexual functions [5]. Both full-
thickness local excision and observation alone without
immediate surgery have been suggested as acceptable al-
ternative organ-preserving treatment strategies for these
patients [5–8].
Ultimately, alternative treatment regimens that could
improve or maximize complete response (CR) rates
could have a significant impact on oncological outcomes
and need for radical surgery in patients with rectal can-
cer. Recently, the incorporation of additional cycles of 5-
Fluorouracil (5FU) based chemotherapy to standard
long-course CRT regimens has resulted in considerably
higher CR rates allowing avoidance of surgery in more
than half of patients with stage I-III rectal cancer [9].
The role of molecular imaging using 18F-fluorodeoxyglu-
cose (FDG) positron emission tomography/computerized
tomography (PET/CT) has been extensively investigated in
the setting of neoadjuvant CRT to predict and assess tumor
response in patients with rectal cancer [10–14]. Besides the
qualitative information provided by this imaging modality,
PET/CT allows objective estimation of tumor metabolism
based on standard uptake values (SUV). In fact, series of
published reports have consistently suggested that greater
decreases in tumor metabolism at different intervals from
CRT completion are associated with improved rates of CR
and overall outcomes [13, 15–18]. In addition, it has been
observed that a significant proportion of patients develop
recuperation of tumor metabolism following standard CRT
regimens between 6 and 12 weeks [19]. This observation
could potentially reflect significant tumor cell death be-
tween baseline and 6 weeks followed by repopulation of
cancer cells between 6 and 12 weeks from CRTcompletion.
Therefore, we decided to investigate tumor metabol-
ism with the use of FDG PET/CT imaging after ex-
tended CRT using additional (consolidation) cycles of
chemotherapy during radiotherapy (RT) and the resting
period in comparison to standard CRT (2 cycles of con-
comitant 5FU-based chemotherapy). One would expect
that regimens with improved rates of complete response
would have more pronounced decreases in tumormetabolism and decreased risk for recuperation of
tumor metabolism after 6 weeks from RT completion.Methods
Consecutive patients with non-metastatic rectal adeno-
carcinoma located up to 7 cm from the anal verge
(assessed by rigid proctoscopy) were eligible for the
study after local IRB-approval (CAPPESQ 717/05; Uni-
versity of São Paulo School of Medicine). Informed con-
sent was obtained from all individual participants
included in the study. Baseline staging and assessment
included full physical and digital rectal examination
(DRE), rigid proctoscopy, endorectal ultrasound (ERUS)
or high-resolution magnetic resonance (MR). Consider-
ing all patients underwent PET/CT, imaging additional
regular chest and abdominal computerized tomography
(CT) scans were omitted for systemic staging. All pa-
tients with cT2-4 N0-2 M0 were included in the study
unless refusal to sign informed consent, refusal to
undergo CRT, pregnancy or age <18 years were present.
There was no difference in policy for the indication to
neoadjuvant CRT between the two cohorts.Neoadjuvant CRT
Standard CRT regimen - NCT00254683
Patients undergoing standard CRT have been previously
described from the prospective trial registered under
NCT00254683 that recruited patients between 2005 and
2009 at the University of São Paulo School of Medicine –
Colorectal Surgery Division after IRB approval [14]. Briefly,
all patients underwent 54Gy of radiation and concomitant
chemotherapy (5FU/leucovorin; 5FU 425 mg/m2/d; folinic
acid 20 mg/m2/d) being delivered in the first and last 5 days
of radiation (2 cycles of chemotherapy). A total of
45Gy in daily doses of 180 cGy was delivered to the
pelvis and an additional boost of 9Gy was delivered to
the primary tumor [14].Consolidation CRT regimen
Consecutive patients undergoing extended CRT be-
tween 2012 and 2013 at the Angelita & Joaquim Gama
Institute received 54Gy of radiation using similar frac-
tionation and 5FU-based chemotherapy (5FU/leucov-
orin) as described elsewhere and IRB approval [20].
These patients received a total of 6 cycles of chemo-
therapy (3 consecutive days each with bolus 5FU
450 mg/m2 and a fixed dose of 50 mg of leucovorin)
being delivered during the radiation therapy period
(3 cycles) and additional 3 cycles after radiation com-
pletion (resting period), instead of the 2 usual cycles
in the beginning and end of RT.
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In both groups of patients, clinical assessment of tumor
response was performed uniformly at 12 weeks from RT
completion by two experienced colorectal surgeons
using identical assessment tools used at baseline: Phys-
ical examination, DRE, rigid proctoscopy, ERUS or pel-
vic MR. Patients with clinical and radiological evidence
of complete clinical response (cCR) were not immedi-
ately operated on and were enrolled in a Watch & Wait
surveillance protocol as described elsewhere [21]. Pa-
tients with incomplete clinical response were referred to
immediate radical surgery. Surgeons responsible for the
assessment of response were unaware of PET/CT infor-
mation at the time of assessment. Clinical management
decision did not take PET/CT information into consid-
eration unless unsuspected metastatic disease was de-
tected by any of the 3 studies performed by each patient.
Follow-up of patients with complete clinical response
managed non-operatively was performed with rigid
proctoscopy, CEA and DRE every 1–2 months for the
first year and every 3 months thereafter (up to 3 years of
follow-up). After 3 years, patients were assessed every
6 months until 5 years and yearly thereafter. Radiological
imaging for the pelvis (MR) and distant metastases (CT
scans) were performed every 6 months. Patients under-
going radical surgery were followed every 3 months for
the first 2 years, every 6 months between 2–4 years and
yearly thereafter.Fig. 1 CRT regimens and PET/CT timing during treatment. a Standard CRT
chemotherapy; b Consolidation CRT regimen – 54Gy of radiation associatePET/CT
In both groups (Standard and Consolidation CRT), all
patients underwent baseline PET/CT prior to CRT. Fol-
lowing CRT completion, PET/CT was performed at
6 weeks and at 12 weeks after radiotherapy completion.
All PET/CT scans were obtained after IV injection of
370 MBq of 2-fluorine-18-fluoro-2-deoxy-D-glucose
(FDG) under a 6–12 h fasting period. Fasting serum glu-
cose levels were measured 10–15 min before FDG injec-
tion according to standardized protocol. Data were
acquired using a dedicated LSO-PET/CT scanner (Bio-
graph 16, SIEMENS, IL) as previously described [14].
Whole body imaging was carried out in all patients
covering from the base of skull to the proximal portion
of thighs. Imaging was qualitatively interpreted by a sin-
gle experienced observer (nuclear radiologist expert)
who was unaware of the patients’ clinical-assessment sta-
tus at baseline or following CRT.
SUVmax were recorded for primary tumors in all
studies (baseline, 6-week and 12-week).
PET/CT information was compared between patients
undergoing standard and extended CRT (with consolida-
tion chemotherapy). (Fig. 1).
Statistical analysis
Statistical analysis was performed using SPSS V13.0
(Spss Inc, Chicago Il). Numerical variables were analysed
by student t test and categorical variables were evaluatedregimen – 54Gy of radiation associated to 2 cycles of 5FU based
d to 6 cycles of 5FU based chemotherapy
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tically significant for p < 0.05.
Results
Clinical and radiological outcomes of the 99 patients
undergoing standard CRT enrolled in the prospective
study are available elsewhere [14]. Briefly, of the 99 pa-
tients, 16 developed cCR (16 %) and 7 had pCR (7 %)
after radical surgery (23 % overall CR rate).
Overall, 12 patients underwent extended CRT with
consolidation chemotherapy at the Angelita & Joaquim
Gama Institute between 2012 and 2013. Of these, 7 pa-
tients developed cCR (58 %) and 1 had pCR (8 %) after
this treatment strategy. Patient’s characteristics and
baseline tumor features are available in Table 1. (Fig. 2).
Patients undergoing standard CRT had significantly
more locally advanced disease when compared to con-
solidation CRT group in terms of cT status (cT3: 88 % vs
58 %; p < 0.001). Also, patients were less likely to develop
complete pathological response or complete clinical
response (23 % vs. 66 %; p = 0.004) after standard CRT.
SUVmax
Baseline SUVmax was significantly higher among pa-
tients in the standard CRT group when compared toTable 1 Patient’s characteristics and baseline tumor features
Standard CR
N 99
Gender (M-F) 47 – 52 (47.
Age (years) 60.3 ± 12.7
Tumor size (mm) 43.2 ± 11.6
Distance anal verge (cm) 3.9 ± 2.0
Initial Staging
cT 2 6 (6.1 %)
3 87 (87.9 %)
4 6 (6.1 %)
cN positive 43 (43.4 %)
cUICC I 6 (6.1 %)
II 50 (50.5 %)
III 43 (43.4 %)
TRG 3 or 4 22 (30.1 %)
CR (cCR or pCR) 23 (23.2 %)
Final tumor size (mm) 40.6 ± 22.2
Final Staging
UICC CCR 16 (16.1 %)
pCR 7 (7.1 %)
I 14 (14.1 %)
II 30 (30.3 %)
III 19 (19.2 %)consolidation CRT group (21.5 vs. 14.8; p = 0.004). SUV-
max was also consistently higher in the standard CRT
group at 6 weeks and 12 weeks from CRT (Table 2).
Curiously, percentage variation in SUVmax between
6 weeks and baseline was significantly higher among pa-
tients undergoing consolidation CRT. There was an
88 % reduction in SUVmax at 6 weeks among patients
undergoing extended CRT as opposed to 63 % reduction
among those undergoing standard CRT (p < 0.001). In
addition, the percentage reduction at 12 weeks was even
greater in the consolidation CRT group (90 % vs. 57 %;
p < 0.001). (Fig. 3).
Between 6 and 12 weeks of RT completion, increases
in SUVmax were observed in 46 patients out of 91 that
performed all three PET/CTs (51 %) of the patients on
the standard CRT arm. In contrast, increases in SUVmax
were observed in only 2 patients (18 %) in the consolida-
tion CRT group (p = 0.004).
Discussion
Development of new alternative neoadjuvant regimens
that could potentially increase complete tumor regres-
sion rates could have a major impact in the management
and outcome of rectal cancer patients. Recently, an alter-
native CRT regimen incorporating additional cycles ofT Extended CRT p
12
5 – 52.5) 7 – 5 (58.3 – 41.7) 0.48
58.6 ± 8.4 0.53
43.3 ± 6.5 0.96
4.6 ± 1.3 0.13
5 (41.7 %)
7 (58.3 %)
0 (0.0 %) 0.001
8 (66.7 %) 0.11
3 (25.0 %)
1 (8.3 %)
8 (66.7 %) 0.006
3 (75.0 %) 0.09
8 (66.7 %) 0.004





2 (16.7 %) 0.004
Fig. 2 a PET/CT imaging (baseline / 6 weeks / 12 weeks) in a patient that developed complete clinical response; b MR imaging from the same
patient at baseline and at 12 weeks after CRT
Habr-Gama et al. Radiation Oncology  (2016) 11:24 Page 5 of 85FU-based chemotherapy (consolidation CRT) has re-
sulted in significant increases in cCR rates ultimately
avoiding surgery in more than half of patients with cT2/
T3 rectal cancer [9]. In another recently reported phase
II trial, the addition of multiple mFOLFOX6 cycles after
CRT resulted in progressively higher complete patho-
logical response rates after radical surgery [22].
It has been previously reported that a significant pro-
portion of patients undergoing standard neoadjuvant
CRT present an actual increase in SUVmax after 6 weeks
from CRT completion, suggesting recuperation of meta-
bolic activity of these tumors [19]. Patients that had an
increase of metabolic activity after 6 weeks from stand-
ard CRT were found to have larger final tumor size. de-
creased rates of CR and decreased rates of near-
complete responses. This could suggest that there was
significant tumor repopulation at 6 weeks after standardTable 2 PET/CT characteristics according to neoadjuvant CRT regim
Standard
Baseline SUVmax 21.5 ± 11
6 weeks SUVmax 7.3 ± 6.3
12 weeks SUVmax 8.4 ± 7.4
Complete Response 18 (18.2 %
Δ %SUVmax variation (6 weeks - baseline) 63.8 ± 24
Δ %SUVmax variation (12 weeks - baseline) 57.9 ± 31CRT in a significant proportion of these patients [19]. In
the present study, while 51 % of patients undergoing
standard CRT had any increase in SUVmax between 6
and 12 weeks, only 18 % of patients undergoing ex-
tended CRT with consolidation chemotherapy were
found to have this recuperation in metabolic activity.
Altogether, these data suggest that after consolidation
CRT, the average decrease in tumor metabolism is
greater and tumor repopulation is less frequent when
compared to standard CRT, at least between 6 and
12 weeks. Therefore, postponing assessment of tumor
response after consolidation CRT until 12 weeks seems
to be safer than doing so after standard CRT regimen. It
may seem surprising that a rather modest increase in the
amount of chemotherapy delivered after CRT may have
resulted in such a significant reduction of tumor repopula-
tion. However, one may have to consider that after aen
CRT Extended CRT p
.0 14.8 ± 5.9 0.004
1.9 ± 1.8 0.001
1.3 ± 1.9 0.001
) 8 (66.7 %) 0.001
.1 88.1 ± 10.4 0.001
.5 90.7 ± 13.0 0.001
Fig. 3 Variation in SUVmax between baseline and 6 and 12-week PET/CT; Patients undergoing consolidation CRT had significant increased
variation between baseline and 6 or 12-week PET/CT (<0.001)
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of only residual microscopic foci could ultimately have
been successfully eradicated by these additional cycles. In
fact, the recently reported phase II trial suggests that the
more additional chemotherapy, the higher chance of
complete tumor regression and therefore, lesser chance of
tumor cell repopulation [22]. Considering this latter study,
there is a chance that not only the addition of oxaliplatin
but also the use of more modern 5FU delivery options
(oral or infusional) instead of bolus infusion used in our
study, could contribute to increase response rates and
block tumor cell repopulation.
One could argue that patients in the consolidation regi-
men had the last 2 PET/CTs performed while still on
chemotherapy. This may have influenced the uptake of
FDG by tumors cells resulting in decreased SUVmax
values without representing true histological regression.
This is the reason why it is recommended to perform
FDG-PET imaging at least 2 weeks after completion of
CRT for more reliable treatment monitoring. Still, the ob-
served decreased SUVmax values after consolidation CRT
did seem to correlate with final clinical outcomes by the
overall cCR rates.
Finally, a longer follow-up with further sequential
PET/CT imaging could have shown different outcomes.
Ultimately, tumor repopulation after this extended CRT
regimen may develop longer than 12 weeks. Therefore,
longer follow-up could result in tumor recurrence
(regrowths) after sufficient repopulation of cancer cells
not detectable at 12 weeks due to the considerably small
residual tumor burden. On the other hand, such study
would require an excessive number of PET/CT imaging
both in terms of cost and radiation exposure to these
patients.There have been a number of studies suggesting that a
critical decrease in tumor metabolism that is associated
with the development of a CR seems to be around 65 %
after 6 weeks from CRT [13, 15–18]. Therefore, tumors
that exhibit an average ≥65 % decrease in SUVmax after
6 weeks from CRT are more likely to develop the single
most clinically relevant outcome after CRT for rectal can-
cer: complete response. In our previously reported study,
the average reduction in SUVmax of rectal cancers after
12 weeks from standard CRT was 63 % [19]. In that study,
there was no further reduction in average SUVmax be-
tween 6 and 12 weeks from RT completion when all pa-
tients are considered [19]. However, when only patients
with a complete response are considered, there is further
decrease in SUV values. The critical SUVmax reduction
cutoff considered to be significant for CR development
was ≥67 % at 6 weeks and ≥76 % at 12 weeks. This reduc-
tion was found to be an independent predictor of CR in
that series [15]. In the present study, patients undergoing
neoadjuvant consolidation CRT presented an average
88 % reduction in SUVmax between baseline and 6 week-
PET/CT. This SUVmax reduction was significantly greater
than the observed after standard CRT regimen (88 % vs.
63 %; p < 0.001). Considering that 65 % reduction was crit-
ical to the development of a CR, one could expect that an
88 % average reduction would result in a significant in-
crease in the CR rate of patients undergoing this novel
CRT regimen. In fact, complete response rates were also
significantly higher after consolidation CRT as already
suggested in previous reports and in this independent
group of patients enrolled in this study (66 % vs 23 %; p <
0.001). In fact, even though 12 patients may constitute a
rather small number of patients, the rates of initial CR are
quite similar between the reported series so far [9, 20].
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may have accounted for some of the findings. First, the
number of patients included in the extended consolida-
tion CRT assessed by sequential PET/CT imaging is ra-
ther small and results warrant further investigation in a
larger sample size. As a result of a limited sample size,
even though there was no change in policy for the indi-
cation of neoadjuvant CRT between the two cohorts, pa-
tients in the extended CRT group had more earlier
disease stage (cT2 vs. cT3) that could potentially have
influenced CR rates. Still, the observed metabolism pro-
file and percentage reduction in SUVmax may be pos-
sibly more related to sensitivity to CRT than actual T
classification. Also, baseline SUVmax was significantly
lower in the consolidation CRT group. There are conflic-
tive data to suggest that baseline SUVmax is predictive
of response to CRT in patients with rectal cancer.
Higher SUV values have been associated with improved
response in some studies. However, our data failed to
correlate baseline SUV with response [15]. In addition,
percentage variation rather that crude SUV values would
potentially correct any bias in this direction. Ultimately,
several features may influence individual SUVmax be-
tween tumors that are difficult to control for.
Conclusions
Patients undergoing extended CRT with consolidation
chemotherapy may develop more substantial reduction
in tumor metabolism after 6 weeks from RT completion.
This reduction in tumor metabolism may partially ex-
plain higher rates of complete regression after this treat-
ment regimen. Also, the risk of developing tumor
repopulation and increase in metabolism between 6 and
12 weeks is much lower after consolidation CRT. There-
fore, assessment of tumor response may be safely post-
poned to 12 weeks in patients undergoing extended
CRT (using consolidation chemotherapy) strategy.
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